Omeros Corporation Initiates Sales of OMIDRIA in Europe


Jul 23, 2018--Omeros Corporation today announced initial sales of OMIDRIA A 1%/0.3% in Europe. OMIDRIA, approved and commercially available in the U.S., is also approved in the European Union for use in cataract and lens replacement surgery to maintain mydriasis , prevent miosis , and to reduce postoperative eye pain.



from Biotech News